We then summarize ongoing efforts to develop Hp-specific flavodoxin inhibitors, and, finally, we discuss the possibility of extrapolating them to target the flavodoxins of other gastric pathogens for the treatment of the corresponding infections. This evidence concerns the gene HP and infection.